Page 1

EX - 99.1 2 ex9913q2021 earningspressre.htm EX - 99.1 EXHIBIT 99.1 MIMEDX Announces Third Quarter 2021 Operating and Financial Results Third Quarter Net Sales of $ 63.1 Million Versus $ 64.3 Million in 3Q20 Adjusted Net Sales of $ 62.8 Million Include a 13 % Increase in Core Portfolio Sales Versus 3Q20 Year - to - Date Adjusted Net Sales Increase of 16 % in Core Portfolio Sales Versus Prior Year Period Reflects Expansion in Surgical Applications Company to Host Conference Call on November 3 , 2021 , at 8:30 AM ET -- MARIETTA , Ga . , November 2 , 2021 MiMedx Group , Inc. ( Nasdaq : MDXG ) ( “ MIMEDX ” or the “ Company ” ) , an industry leader in utilizing amniotic tissue as a platform for regenerative medicine , today announced the filing of its third quarter 2021 Form 10 - Q for the period ended September 30 , 2021 . Timothy R. Wright , MIMEDX Chief Executive Officer , commented , " The growth in our core portfolio of tissue and cord products this quarter demonstrates consistent execution on multiple initiatives designed to reinforce and convey the differentiation , clinical evidence and economic value of our brands . We are expanding our presence in surgical applications with our AMNIOFIX® brand and continuing to gain traction with our EPICORD® Expandable product line , which enables customers to address a broader range of lower extremity wounds in a cost - effective way . The success in our base business fuels our investments in clinical operations , medical education , and product development initiatives including portfolio innovation and expansion , ultimately driving better outcomes for patients in need of advanced , evidence - based treatment options . " Mr. Wright continued , “ Since announcing the top - line data from our late - stage musculoskeletal clinical trials in mid- September , we have been extensively reviewing the study results to determine the reasons behind the observed differences between patient cohorts in the Knee Osteoarthritis ( KOA ) trial . As part of our statistical analysis plan , third - party biostatisticians have validated the probability values ( p - values ) from the Phase 2B KOA study and substantiated both a statistically significant and clinically meaningful outcome in Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) Total , WOMAC Pain , and WOMAC Function scores for the Pre - Interim Analysis Cohort of 190 patients , with p - values less than 0.05 at three months and less than 0.01 at six months . These positive efficacy signals , while limited to the Pre - Interim Analysis Cohort of 190 patients , provide us with important insights into our approach for our future Phase 3 studies , and we are confident in the therapeutic potential of micronized